Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2025 |
Jan. 31, 2026 |
Jun. 30, 2025 |
|||
| Document Information [Line Items] | |||||
| Document Type | 10-K | ||||
| Document Annual Report | true | ||||
| Document Transition Report | false | ||||
| Document Financial Statement Error Correction [Flag] | false | ||||
| ICFR Auditor Attestation Flag | false | ||||
| Amendment Flag | false | ||||
| Document Period End Date | Dec. 31, 2025 | ||||
| Document Fiscal Year Focus | 2025 | ||||
| Document Fiscal Period Focus | FY | ||||
| Entity Registrant Name | Silence Therapeutics plc | ||||
| Entity Central Index Key | 0001479615 | ||||
| Entity File Number | 001-39487 | ||||
| Entity Tax Identification Number | 00-0000000 | ||||
| Entity Incorporation, State or Country Code | X0 | ||||
| Current Fiscal Year End Date | --12-31 | ||||
| Entity Well-known Seasoned Issuer | No | ||||
| Entity Voluntary Filers | No | ||||
| Entity Current Reporting Status | Yes | ||||
| Entity Interactive Data Current | Yes | ||||
| Entity Shell Company | false | ||||
| Entity Filer Category | Non-accelerated Filer | ||||
| Entity Small Business | true | ||||
| Entity Emerging Growth Company | false | ||||
| Entity Public Float | $ 206.2 | ||||
| Entity Address, Address Line One | 12 Hammersmith Grove | ||||
| Entity Address, City or Town | London | ||||
| Entity Address, Country | GB | ||||
| Entity Address, Postal Zip Code | W6 7AP | ||||
| City Area Code | +44 20 | ||||
| Local Phone Number | 3457 6900 | ||||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2026 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2025. |
||||
| Auditor Firm ID | 876 | ||||
| Auditor Location | Reading, United Kingdom | ||||
| Auditor Name | PricewaterhouseCoopers LLP | ||||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Silence Therapeutics plc and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of income (loss), of comprehensive income (loss), of changes in shareholders’ equity and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America |
||||
| Entity Common Stock, Shares Outstanding | 141,701,848 | ||||
| American Depositary Shares | |||||
| Document Information [Line Items] | |||||
| Title of 12(b) Security | American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per share | ||||
| Trading Symbol | SLN | ||||
| Security Exchange Name | NASDAQ | ||||
| Ordinary Shares | |||||
| Document Information [Line Items] | |||||
| Title of 12(b) Security | Ordinary share, nominal value £0.05 per share | ||||
| No Trading Symbol Flag | true | ||||
| Security Exchange Name | [1] | NASDAQ | |||
| |||||